Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on LinkedIn:
“Atezolizumab and Nab-paclitaxel still remain as one of the options for mTNBC, but we should be wary of these 2 negative studies
- IMpassion 131: the same atezolizumab combination with conventional paclitaxel didn’t show benefit
- IMpassion 132: atezolizumab and chemotherapy don’t work in early progressors.”
More posts featuring Akhil Santhosh.
